Collegium Pharmaceutical, Inc. 已达成协议,将从Corium Therapeutics公司收购注意力缺陷多动障碍(ADHD)治疗药物Azstarys®。此次收购旨在显著增强Collegium在ADHD治疗领域的市场地位,并有力推动其未来的业务增长轨迹。
Collegium Pharmaceutical, Inc. 已达成协议,将从Corium Therapeutics公司收购注意力缺陷多动障碍(ADHD)治疗药物Azstarys®。此次收购旨在显著增强Collegium在ADHD治疗领域的市场地位,并有力推动其未来的业务增长轨迹。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.